Newsletter
Every new paper in this field, in your inbox.
Endoscopic treatment and surgery show similar overall and cancer-specific survival rates in gastrointestinal neuroendocrine neoplasms. Endoscopic treatment may offer a better cancer-specific survival in certain cases such as stage I tumors and those smaller than 10mm. Both treatment options are viable for patients, with endoscopic…
Minimally invasive surgery (MIS) shows comparable long-term survival outcomes to open surgery for ileal neuroendocrine tumors (i-NETs), with no significant difference in overall survival rates at around 99 to 103 months follow-up. MIS is a viable alternative for i-NETs resection, especially in cases without bulky…
Establishing a dedicated multidisciplinary tumor board significantly improved surgical outcomes for retroperitoneal sarcoma patients. The post-clinic era saw a marked increase in annual surgeries from 16.3 to 42.4 (p = 0.001), and a rise in complex resections (49% vs. 18.2%; p = 0.0001). These changes…
Meta-analysis findings show that neoadjuvant imatinib achieves high 1-year, 3-year, and 5-year overall survival rates of 100%, 94%, and 88%, respectively. Patients with gastric and rectal tumors benefit most with an 8-month treatment duration. Additionally, mutational analysis can aid in treatment decision-making. Effective outcomes include…
MRI effectively predicts histological grades of soft tissue sarcomas. Peritumoral high-intensity T2-weighted signals and peritumoral postcontrast enhancement are valuable indicators of high-grade tumors. The study's findings highlight the importance of MRI in treatment decision-making for sarcoma patients, with each score point increment doubling the chance…
Colorectal neuroendocrine neoplasms prognosis in surgical treatment can be predicted by lymph node staging systems like LNR, PLN, and LODDS. A cohort study of 895 patients showed significant predictive values for mortality. After adjusting confounders, these systems were linked with patient outcomes, proving their effectiveness…
Favorable short-term and long-term outcomes were observed in patients undergoing robotic radical surgery for rectal gastrointestinal stromal tumor (GIST), with 100% 5-year overall survival and recurrence-free survival rates. The majority of patients had negative surgical margins, underwent sphincter-preserving surgery, and experienced low postoperative complication rates,…
Endoscopic resection is a safe and effective method for treating intermediate- or high-risk gastric small gastrointestinal stromal tumors, with a 5-year overall survival rate of 97.4%. Close follow-up is necessary for these patients, but there were no recurrences or metastases observed, even among those with…
Imatinib combined with hepatic resection significantly improves overall survival in patients with gastrointestinal stromal tumor liver metastases compared to imatinib monotherapy. Achieving no evidence of disease status through surgical intervention leads to prolonged overall survival, liver-specific progression-free survival, and progression-free survival. Age ≤60 years and…
A combined model integrating clinical and contrast-enhanced computed tomography (CE-CT) features accurately predicts specific genetic mutations in gastrointestinal stromal tumors (GISTs). Researchers developed three models from data from 231 GIST patients, with the best model achieving high accuracy in predicting molecular subtypes. In the training…
